Forged in Fire: My Journey with Biliary Atresia from 115 Pounds to a Life of Purpose
To the patient, the parent, the caregiver, and the person in the "limbo" of waiting: I am one of you. My name is Aaron Jackson, and this is my story.…
To the patient, the parent, the caregiver, and the person in the "limbo" of waiting: I am one of you. My name is Aaron Jackson, and this is my story.…
Unfortunately, clinical studies do not always work out the way they’re expected to. Biopharmaceutical company Mirum Pharmaceuticals, Inc. (“Mirum”) learned this after the Phase 2 EMBARK trial failed to meet…
According to a press release from the rare liver disease company Albireo Pharma, Inc., the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for odevixibat.…
According to a recent press release from Albireo Pharma, the first participant has enrolled in the BOLD trial. The BOLD trial, which stands for Biliary atresia and the use…
According to a story from Market Screener, the drug developer Albireo Pharma, Inc., recently announced that its investigational product candidate A4250 has earned Orphan Drug designation from the European Commission.…
Aidan Maddocks, 14, from Pietermaritzburg, was diagnosed with Biliary Atresia at birth, a childhood liver disease that only affects 1 in 10,000–15,000 live births. He was given a life expectancy…
Ryan Cole is a beautiful baby. You would never know from looking at him that he was struggling for life fighting a rare disease called biliary atresia, reported Courier Mail.…
It was a Christmas miracle for the Garcia family as their infant quickly recovered and was discharged from the hospital to enjoy the holiday at home, reported DailyMail. 1-year-old baby…
During a time when we get a lot of bad or polarizing news about the world, it's important to highlight the good stuff - so here is some good stuff…
Leave it to a sports award show to recognize what a real fighter looks like. ESPN's annual award show (the ESPYs) honored 15 year-old Jarrius Robertson last week with the…